Read More

Why Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors’ Radars Today

On Wednesday, key U.S. stock indexes closed lower, as the Dow Jones Industrial Average fell by 1.1% to 38,461.51, the S&P 500 dropped nearly 1% to 5,160.64, and the Nasdaq ended the day down by 0.8% at 16,170.36. These are the top stocks that gained the attention of retail traders and investors throughout the day:

ADIL

Read More

Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck’s Pneumococcal Shots – Analyst Says

The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the US discussing vaccination age reduction. Prevnar20 dominates with 97% market share in adults, but Vaxcyte's advanced conjugate capabilities present a competitive advantage.

MRK

Read More

Cartesian Therapeutics’ Rare Disease Candidate Shows Long Lasting Benefit Over Argenx’s Vyvgart, Analyst Initiates With Buy

Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising anti-BCMA CAR-T therapy offering deeper, longer-lasting efficacy than current standards. Analysts project substantial market capture and peak sales potential.

ARGX